BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $246,612 | +4.0% | 3,441 | +2.1% | 0.01% | 0.0% |
Q1 2024 | $237,204 | -2.7% | 3,370 | +6.7% | 0.01% | -16.7% |
Q4 2023 | $243,722 | +43.9% | 3,159 | +27.0% | 0.01% | +50.0% |
Q3 2023 | $169,417 | -67.2% | 2,488 | -44.0% | 0.01% | -27.3% |
Q2 2023 | $516,925 | +1122.9% | 4,444 | +1487.1% | 0.01% | +450.0% |
Q1 2023 | $42,271 | +52738.8% | 280 | -46.3% | 0.00% | 0.0% |
Q4 2022 | $80 | -99.8% | 521 | +202.9% | 0.00% | +100.0% |
Q3 2022 | $39,000 | 0.0% | 172 | -2.3% | 0.00% | 0.0% |
Q2 2022 | $39,000 | -48.0% | 176 | -53.4% | 0.00% | 0.0% |
Q1 2022 | $75,000 | -9.6% | 378 | +140.8% | 0.00% | -50.0% |
Q4 2021 | $83,000 | +31.7% | 157 | +20.8% | 0.00% | +100.0% |
Q3 2021 | $63,000 | +1.6% | 130 | -11.6% | 0.00% | 0.0% |
Q2 2021 | $62,000 | +19.2% | 147 | +1.4% | 0.00% | 0.0% |
Q1 2021 | $52,000 | +333.3% | 145 | +202.1% | 0.00% | – |
Q4 2020 | $12,000 | +140.0% | 48 | +152.6% | 0.00% | – |
Q3 2020 | $5,000 | 0.0% | 19 | 0.0% | 0.00% | – |
Q2 2020 | $5,000 | +25.0% | 19 | -9.5% | 0.00% | – |
Q1 2020 | $4,000 | -73.3% | 21 | -70.8% | 0.00% | -100.0% |
Q4 2019 | $15,000 | +25.0% | 72 | +20.0% | 0.00% | 0.0% |
Q3 2019 | $12,000 | +300.0% | 60 | +200.0% | 0.00% | – |
Q4 2018 | $3,000 | -78.6% | 20 | -70.1% | 0.00% | -100.0% |
Q3 2018 | $14,000 | +55.6% | 67 | +4.7% | 0.00% | – |
Q2 2018 | $9,000 | 0.0% | 64 | -3.0% | 0.00% | – |
Q1 2018 | $9,000 | 0.0% | 66 | 0.0% | 0.00% | – |
Q4 2017 | $9,000 | +12.5% | 66 | 0.0% | 0.00% | – |
Q3 2017 | $8,000 | 0.0% | 66 | 0.0% | 0.00% | – |
Q2 2017 | $8,000 | +14.3% | 66 | 0.0% | 0.00% | – |
Q1 2017 | $7,000 | +40.0% | 66 | +29.4% | 0.00% | – |
Q4 2016 | $5,000 | +400.0% | 51 | +325.0% | 0.00% | – |
Q3 2016 | $1,000 | -66.7% | 12 | -50.0% | 0.00% | – |
Q2 2016 | $3,000 | -40.0% | 24 | -52.9% | 0.00% | – |
Q4 2015 | $5,000 | – | 51 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |